CRDF logo

CRDF Cardiff Oncology, Inc.

NASDAQ · Biotechnology · Healthcare

$0.73
-0.00 (-0.21%)

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in …

Market Cap: $56.49Mwww.cardiffoncology.com

Price

No data yet.

Social Signal Score

34
5d
—
30d
30
2 mentions
—
60d
33
3 mentions
—
90d
40
5 mentions
—
news: 5

Analyst Ratings

15 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 6Sell 1Strong Sell 0
Avg price target$2+175.4%
Low $2Median $2High $2
Current Consensus

Revenue

$171.0K+151.47%
$41.0K$108.3K$175.7K$243.0K
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.77
$-0.79–$-0.75
6 analysts
FY2026
$-0.56
$-0.60–$-0.52
3 analysts
FY2027
$-0.62
$-0.83–$-0.36
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Mani Mohindru
Sector
Healthcare
Industry
Biotechnology
Employees
31
Beta
1.56
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-16.14
www.cardiffoncology.com